IDO1 and cancer: Upregulation of IDO in cancer cells and some immune cells is mediated by inflammatory cytokines such as interferon (INF)‐γ, and aPD‐1 therapy can therefore increase IDO expression due to the increased release of INF‐γ by restored cytotoxic T‐cells, which counteracts the therapeutic benefit of aPD‐1 therapy.11